L3VLUP
ProSign in

NVO · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NVOLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NVO
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterNVOLLY
Q3 20207 holders, $2.2bn33 holders, $14.1bn
Q4 20205 holders, $2.0bn29 holders, $17.3bn
Q1 20214 holders, $1.8bn24 holders, $23.0bn
Q2 20215 holders, $2.2bn24 holders, $27.8bn
Q3 20217 holders, $2.4bn31 holders, $29.9bn
Q4 20216 holders, $2.5bn31 holders, $34.7bn
Q1 20227 holders, $2.4bn24 holders, $35.3bn
Q2 202210 holders, $2.5bn33 holders, $42.7bn
Q3 20227 holders, $1.8bn31 holders, $43.4bn
Q4 202212 holders, $3.1bn31 holders, $46.6bn
Q1 202314 holders, $3.8bn33 holders, $44.3bn
Q2 202317 holders, $4.3bn37 holders, $59.6bn
Q3 202320 holders, $5.6bn44 holders, $67.6bn
Q4 202323 holders, $6.0bn45 holders, $73.6bn
Q1 202417 holders, $7.3bn41 holders, $95.3bn
Q2 202424 holders, $8.7bn43 holders, $110bn
Q3 202423 holders, $6.5bn45 holders, $107bn
Q4 202421 holders, $4.3bn46 holders, $93.9bn
Q1 202518 holders, $2.8bn42 holders, $98.4bn
Q2 202515 holders, $2.4bn43 holders, $93.2bn
Q3 202515 holders, $1.6bn39 holders, $86.7bn
Q4 202512 holders, $1.6bn41 holders, $123bn
Q1 202617 holders, $2.9bn39 holders, $106bn
Q2 202615 holders, $3.0bn44 holders, $132bn
NVO

Novo-nordisk A S

Holders
24
Reported value
$8.7bn
Buyers
15
Sellers
7

Breadth +8 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
43
Reported value
$110bn
Buyers
29
Sellers
17

Breadth +12 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 49 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only NVO (6)

Baillie Gifford & Co, Markel Group Inc, Maverick Capital Ltd, Point72 Asset Management LP, Renaissance Technologies LLC, Soros Fund Management LLC

Only LLY (25)

AllianceBernstein LP, AQR Capital Management LLC, Bridgewater Associates LP, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, GAMCO Investors Inc, Invesco Ltd, Jane Street Group LLC, Man Group PLC, MFS Investment Management, Moore Capital Management LP, Neuberger Berman Group LLC, Quantbot Technologies LP, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, Susquehanna International Group LLP, Two Sigma Investments LP, Verition Fund Management LLC, Viking Global Investors LP, Wellington Management Group LLP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →